Table 3 Clinical features of the 16 advanced-stage pulmonary lymphoepithelioma-like carcinoma patients

From: A multicenter analysis of genomic profiles and PD-L1 expression of primary lymphoepithelioma-like carcinoma of the lung

Patient ID

Age

Gender

Smoking status, smoking pack year

Disease stage

Treatment regimen received

Best response

Immunotherapy, best response

# of CNVs detected

TMB (mutations/Mb)

PD-L1 TPS (%)

Degree of lymphoid cell infiltration

Date of diagnosis

OS as of last follow-up date (months)

Survival status

P09

48

Male

No

IIIB

CT

PR

No

2

0

0

40%

2016/6/27

30.0

Alive

P19

55

Female

No

IIIB

CT

No

0

1.6

10

40%

2018/11/13

1.0

Alive

P21

66

Female

No

IIIB

CT

SD

No

0

0.8

0

1%

2018/8/21

3.7

Alive

P28a

49

Female

No

IIIB

CT

 

Nivolumab, SD

 

60

5%

2017/4/12

19.0

Alive

P25

45

Male

Smoker, 3

IIIC

CT

No

7

6.3

0

30%

2018/5/5

6.7

Alive

P26

57

Male

Smoker, 40

IIIC

CT + RT

SD

No

1

2.4

10

30%

2018/6/10

4.6

Alive

P06

32

Female

Non-smoker (exposure to second-hand smoke)

IVA

Neo CT + S + adj CT

PR

No

7

2.4

10

8%

2016/11/17

25.3

Alive

P07

76

Male

No

IVA

CT + RT

SD

No

8

3.2

0

10%

2017/4/6

20.7

Alive

P13

49

Male

Smoker, 20

IVA

CT

PR

No

1

0

30

30%

2018/7/13

5.0

Alive

P12

60

Female

No

IVA

CT

PR

No

4

15.9

30

10%

2018/7/9

4.9

Alive

P03

65

Female

No

IVA

Not treated

No

5

0.8

10

30%

2016/11/28

22.7

Alive

P29a

48

Male

No

IVA

CT

 

SHR-1201, SD

15

5%

2017/2/28

13.0

Alive

P11

24

Female

No

IVB

CT

PR

No

3

5.6

20

40%

2018/3/15

9.0

Alive

P16

65

Female

No

IVB

CT

SD

No

7

2.4

0

10%

2015/8/9

40.7

Alive

P18

39

Female

No

IVB

CT

SD

No

0

1.6

80

10%

2018/10/31

1.9

Alive

P10

40

Male

Smoker, 15

IVB

Not treated

No

2

0

5

5%

2018/3/29

7.1

Alive

  1. – Data not available
  2. Adj CT adjuvant chemotherapy,CNV copy number variation, CT chemotherapy, Neo CT neoadjuvant chemotherapy, OS overall survival, PR partial response, RT radiotherapy, S surgery, SD stable disease, TMB tumor mutation burden, TPS tumor positive score
  3. aPatients P28 and P29 did not have adequate tissue samples for genomic profiling